InvestSMART

INOVIQ Ltd (ASX:IIQ)

ALERT: Price-sensitive ASX Announcement for IIQ
Current share price for IIQ : $0.210 -0.01 (-4.55%)+
Announcement
Release
14 Jul 2026 9:49AM
Price at Release
$0.220
Full Release
download
Summary
INOVIQ Ltd conducted an investor webinar detailing the EXO-OC test, which leverages exosomal biomarkers and CA125 with AI/ML algorithms for the early detection of ovarian cancer. The study used a retrospective case-control design and demonstrated 100% sensitivity for early stages and over 99.6% specificity. The EXO-OC test is designed for dual commercialisation as a Laboratory Developed Test for high-risk women and an In Vitro Diagnostic for average-risk postmenopausal women, with regulatory approvals being pursued globally. The test aims to address the significant unmet need for ovarian cancer screening, with INOVIQ committed to further validation and commercialisation efforts.
Key Points
  • INOVIQ Ltd presented an investor webinar on the EXO-OC test.
  • The EXO-OC test uses exosomal biomarkers and CA125 integrated with AI/ML algorithms for early detection of ovarian cancer.
  • The study used a retrospective case-control design with biobanked plasma samples.
  • The test achieved 100% sensitivity for Stage I/II and >99.6% specificity overall.
  • The test is intended for both high-risk women as a Laboratory Developed Test (LDT) and average-risk postmenopausal women as an In Vitro Diagnostic (IVD).
  • Dual commercialisation paths are planned for the EXO-OC test as both LDT and IVD.
  • Regulatory approvals are being sought in multiple regions, including the US FDA and Australian ARTG.
  • The EXO-OC test seeks to address the unmet need for ovarian cancer screening.
  • INOVIQ plans to continue validating and commercialising the EXO-OC test.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.